CHO-DXB11 Cell Line Adaptation for Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of recombinant proteins for therapeutic use, such as antibodies, is a costly and arduous process, particularly due to challenges in yield, productivity, ease of purification, and cost of goods, with existing mammalian cell culture systems facing limitations in efficiency and cost-effectiveness.
Innovation Solution
The development of an isolated Chinese Hamster Ovary (CHO) cell line, CHO-DXB11, adapted into animal-component free medium in suspension for 83 days and subcloned twice, combined with specific vector constructs encoding immunoglobulin chains and CDRs, to enhance protein production efficiency and reduce production costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional mammalian cell culture systems (CHO or NS0 cell lines) are used for antibody production, then the glycosylation pattern and biological activity are maintained, but the production yield and cost-effectiveness are limited
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including serum-free medium composition, pH control (6.8-7.2), temperature (36.5-37°C), and dissolved oxygen (40-60%) to enhance cell growth and antibody production while maintaining proper glycosylation patterns in the CHO-DXB11 cell line
2Productivity
If cell density is increased to improve protein production, then the quantity of therapeutic protein per liter increases, but the culture conditions and cell viability become more challenging to maintain
Solution Approach 1:
The patent implements dynamic control of culture parameters including gradual pH adjustment from 7.2 to 6.8 over time, temperature shifts from 37°C to 36.5°C, and progressive increase in dissolved oxygen from 40% to 60% to maintain cell viability and culture stability at high cell densities
3Ease of manufacture
If animal-component free medium is used to reduce production costs and simplify purification, then the cost of goods decreases, but the cell growth and adaptation period increase
Solution Approach 1:
The patent applies preliminary action by pre-adapting the CHO-DXB11 cell line to serum-free medium conditions through a structured 14-day adaptation protocol with gradual medium replacement, preparing the cells for subsequent production in animal-component free medium and reducing the overall development time
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides, inter alia, an isolated cell line, 3M as well as methods for making such a cell line and methods of using such a cell line, e.g., to produce a protein such as an immunoglobulin.